Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
ID: 360905Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360905
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Carcinogen Hazard Assessment Monographs Program (CHAMP), a federal grant opportunity aimed at critically evaluating scientific evidence on carcinogenic hazards to humans. This initiative is essential for advancing cancer research and informing cancer control and prevention efforts, as the resulting monographs will serve as key references that shape health policy and regulation to help reduce the cancer burden. Eligible applicants include various entities such as Indian/Native American Tribal Governments, federal agencies, U.S. territories, regional organizations, and foreign institutions, with no cost-sharing or matching requirements. Interested parties can contact Dr. Tram Kim Lam at lamt@mail.nih.gov or by phone at 240-276-6967 for further information. The estimated award date is October 1, 2026, with applications accepted until June 30, 2026.

    Point(s) of Contact
    Tram Kim Lam, PhD, MPH
    (240) 276-6967
    lamt@mail.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)" aimed at fostering long-term partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs). This initiative seeks to enhance cancer research by addressing disparities in cancer outcomes and promoting outreach and engagement across diverse populations. The program anticipates awarding approximately 12 cooperative agreements, with a minimum funding amount of $850,000, and key deadlines include an estimated synopsis close date of January 16, 2026, and an expected award date of September 1, 2026. For further inquiries, interested applicants can contact Dr. Sandra San Miguel-Majors at 240-276-5977 or via email at ncicpachU54@mail.nih.gov.
    Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Impacts of Climate Change Across the Cancer Control Continuum," aimed at supporting innovative research on the effects of climate change on cancer risks, control, and survivorship. This R21 Exploratory/Developmental Research Grant encourages multidisciplinary studies that explore the relationship between climate change and cancer-related health disparities, necessitating collaboration with climate change experts. The grant offers a budget cap of $275,000 for a two-year project period, with applications opening on January 16, 2025, and closing on May 7, 2026. Interested applicants can find more information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    High-Priority Research in Tobacco Regulatory Science (Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "High-Priority Research in Tobacco Regulatory Science (Clinical Trial Optional)" aimed at supporting research that informs the FDA's tobacco regulatory authorities. This initiative seeks applications for high-priority research projects that address topics such as addiction, behavior, health effects, product composition, and toxicity, with the goal of enhancing the scientific data available for tobacco product regulation. The total estimated funding for this program is $7 million, with an award ceiling of $500,000 and an expected eight awards to be made. Interested applicants can reach out to Erik Rodriquez, Ph.D., M.P.H., at TRSP@nih.gov or by phone at 301-827-2830, with applications due by May 4, 2026, and awards expected to be announced by December 4, 2026.
    Forecast to Publish a Funding Opportunity Announcement for Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the establishment of cancer epidemiology cohorts through the "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts" initiative. This cooperative agreement aims to address critical knowledge gaps in cancer etiology and survivorship by laying the groundwork for future studies that will explore various factors influencing cancer risk and outcomes. Eligible applicants for this discretionary grant include small businesses, with no cost-sharing or matching requirements. Interested parties should note that the estimated synopsis post date is August 1, 2025, and applications are due by November 5, 2025, with awards expected to be made by July 1, 2026. For further inquiries, contact Naoko Ishibe Simonds, Sc.D., or Lisa Gallicchio, Ph.D., at 240-276-6967 or via email at naoko.simonds@nih.gov.
    Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)" aimed at investigating the biological and genetic mechanisms underlying cancer health disparities among diverse racial and ethnic populations. This funding initiative encourages innovative pilot studies that focus on identifying cancer risk factors, developing preventative strategies, and enhancing research methodologies, while fostering a multidisciplinary cohort dedicated to cancer health disparities research. Eligible applicants include a wide range of entities such as educational institutions, nonprofits, and tribal organizations, with a maximum funding amount of $275,000 available for a two-year project period. Interested parties should note that the application deadline is November 16, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-244.html for further details.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing cancer burdens through advancements in early detection, prevention, and healthcare delivery. This funding opportunity, identified as PAR-25-167, specifically excludes trials focused on cancer diagnosis or oncologic therapies in patients, emphasizing the importance of improving public health and clinical practices related to cancer. Eligible applicants include a wide range of organizations, such as academic institutions, non-profits, and tribal governments, with applications due by February 5, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-167.html.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
    Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R01 Clinical Trial Optional)" aimed at supporting research projects that evaluate policies related to tobacco, alcohol, and cannabis use in the United States. The initiative focuses on understanding how these policies impact substance use and secondhand exposure among populations experiencing health disparities, with an emphasis on community engagement to enhance cancer prevention efforts. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and government entities, with funding available up to $500,000 per year for a maximum of five years. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for January 7, 2028.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)." This initiative encourages applications that propose innovative secondary data analyses and integration of existing datasets to address significant scientific questions related to cancer risk, prevention, and treatment outcomes. The program aims to leverage diverse data sources, including clinical, environmental, and genomic datasets, to enhance understanding of cancer and improve public health strategies. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and tribal governments, with a maximum funding amount of $200,000 and a project duration of up to two years. Interested parties can find more information and application details at the NIH grants website, with the submission deadline set for September 7, 2026.